Contineum Therapeutics paper sharpens PIPE-791 case, but Phase 2 IPF data remain decisive
Discover why Contineum Therapeutics’ PIPE-791 paper strengthens the LPAR1 case while Phase 2 IPF data remain the decisive clinical test.
Pharma & Biotech
Pharma & Biotech
Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.